MedTrace Logo

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

NCT00178620 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2023-09-06

Study results available
· View outcomes & findings →

Summary

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates.

Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

Conditions

Interventions

DRUG

Reteplase 10 Units (U) plus a second dose of reteplase 10 U

Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose

DRUG

Reteplase 10 U

Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose

PROCEDURE

Urgent Percutaneous Coronary Intervention (PCI)

PROCEDURE

Primary Percutaneous Coronary Intervention (PCI)

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Richard W. Smalling, MD, PhD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00178620 on ClinicalTrials.gov